이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

새로 진단된 폐암 환자를 포함하여 흉부 종양학의 전향적 종단적 생물 수집 (BREATHE)

2026년 9월 30일 업데이트: Nantes University Hospital

BREATHE 코호트: 새로 진단된 폐암 환자를 포함하여 흉부 종양학의 전향적 종단적 생물 수집

In clinical trials, patients are selected according to strict eligibility criteria (inclusion and exclusion criteria). These criteria aim to ensure homogeneity within the trial population, but may omit patients with specific characteristics, comorbidities or co-medications. Indeed, patients of advanced age, with comorbidities or brain metastases, who are frequently encountered in clinical practice, are often excluded from clinical trials. Real-life data in oncology play a vital role in assessing the efficacy of therapies and therapeutic strategies, complementing data from controlled clinical trials. They make it possible to analyze a larger population and take into account multiple variables such as patient history, co-medications and comorbidities, but also to analyze efficacy and toxicity data in populations not represented in clinical trials. The establishment of a prospective cohort including various stages and histologies will make it possible to set up a platform of available data, including a maximum of data linked to the patient, his tumor and his treatments, collected longitudinally until the patient's death (or the end of the study).

In parallel with this cohort, the project aims to set up a longitudinal plasmatheque (from diagnosis to death, or at the end of the study), as well as a tumorotheque (samples systematically stored as part of care by the CHU tumorotheque, and for which patient consent allows their use in research depending on the material available) for patients with available tumor samples. This will enable the construction of ancillary projects to validate research hypotheses, for example concerning the identification of mechanisms of resistance to therapies.

연구 개요

연구 유형

중재적

등록 (추정된)

730

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Angers, 프랑스
        • 아직 모집하지 않음
        • CHU d'Angers
        • 연락하다:
        • 수석 연구원:
          • Grégoire JUSTEAU
      • Nantes, 프랑스
        • 모병
        • CHU Nantes
        • 연락하다:
      • Rennes, 프랑스
        • 아직 모집하지 않음
        • CHU Rennes
        • 수석 연구원:
          • Charles RICORDEL
        • 연락하다:
      • Tours, 프랑스
        • 아직 모집하지 않음
        • CHU Tours
        • 연락하다:
        • 수석 연구원:
          • Marion FERREIRA

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

Patients :

  • Adult
  • Patient newly diagnosed with NSCLC or CPC
  • Cared for at Nantes University Hospital
  • Affiliated or beneficiaries of a social security scheme or similar
  • Treated with a systemic therapy including chemotherapy and/or immunotherapy and/or targeted therapy and/or therapy as part of a clinical trial after agreement from the sponsors of the studies concerned (only in the absence of blinding).
  • Having agreed to participate in this study by signing the biocollection consent.

Healthy subjects :

  • Adult
  • Affiliated or beneficiaries of a social security or similar scheme
  • Who have agreed to participate in this study by signing the Biocollection consent form.
  • No known infectious pathology
  • No known history of cancer
  • No known history of chronic autoimmune disease
  • No background immuno-suppressive treatment

Ancillary Study :

-Metastatic NSCLC with a KRAS G12C mutation, receiving treatment with Sotorasib, Adagrasib, or another KRAS G12C inhibitor, either as monotherapy or in combination.

Exclusion Criteria:

Patients :

  • Previous anticancer treatment for Lung cancer
  • Patients who have not consented to participate in the BREATHE collection
  • History of cancer (excluding thoracic cancer) with evidence of disease for less than 2 years
  • Inclusion in a therapeutic trial with blinded treatment
  • Patients under guardianship
  • Patients with AME.
  • Pregnant or breast-feeding women

Healthy subjects :

  • Person under guardianship
  • Person benefiting from AME (State medical aid)
  • Pregnant or breast-feeding women

Ancillary Study :

- Pregnant or breast-feeding women

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
다른: Cohort A

Patients are prospectively enrolled the day before their surgery for lung cancer, following selection based on tumor size assessed by the latest CT scan. The lesion size must be ≥ 20 mm (to prioritize anatomopathological analyses performed as part of care). If patients receive adjuvant treatment, blood samples will be collected on the day of treatment initiation and during follow-up. Patients receiving neoadjuvant treatment will be enrolled at the time of their first consultation with the medical oncologist.

Patients in this cohort must meet the following criteria:

- Stage I / II / IIIA-B localized NSCLC (non-small-cell lung cancer) eligible for surgery and adjuvant or neoadjuvant therapy (15-20% of NSCLC)

Intervention : patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

다른: Cohort B

Patients are prospectively enrolled at the diagnosis of lung neoplasm, during the establishment of the therapeutic plan by the referring oncologist or pneumo-oncologist. Enrollment can also occur at the initiation of first-line treatment if it was not done at the time of the diagnostic consultation.

Patients in this cohort must meet the following criteria:

- metastatic NSCLC or SCLC (small-cell bronchial cancers), with drained or punctured pleural effusion and anatomopathological evidence of tumor cells

Intervention, the following volumes of blood will be drawn at each visit :

  • 2*8ml (EDTA tubes)
  • 1*8mL PBMC (only for patients receiving immunotherapy, collected before the 1st course of treatment, before the 2nd course of treatment, and at relapse)
  • 1*6mL Paxgene (only for patients with lung cancer of non-epidermoid histology, collected at 1st treatment, 2nd treatment and relapse)

Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

Patients will be sampled from 1 x 8 mL PBMC

Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube

다른: Cohort C

Cohort C patients are recruited in the same way as for cohort B.

Patients in this cohort must meet the following criteria:

  • Metastatic NSCLC receiving systemic chemotherapy, immunotherapy and/or targeted therapy
  • Locally advanced stage III NSCLC treated with radio-chemotherapy +/- immunotherapy
  • Extra-thoracic SCLC treated with chemotherapy +/- immunotherapy
  • Intra-thoracic SCLC treated with radio-chemotherapy

Intervention, the following volumes of blood will be drawn at each visit :

  • 2*8ml (EDTA tubes)
  • 1*8mL PBMC (only for patients receiving immunotherapy, collected before the 1st course of treatment, before the 2nd course of treatment, and at relapse)
  • 1*6mL Paxgene (only for patients with lung cancer of non-epidermoid histology, collected at 1st treatment, 2nd treatment and relapse)

Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

Patients will be sampled from 1 x 8 mL PBMC

Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube

다른: Cohort BMB

Patients are enrolled preoperatively, at the diagnosis of metastatic lung cancer at the cerebral level. The patient signs consent preoperatively (consent provided by the neurosurgeon). Subsequently, they are prospectively followed as part of their management in medical oncology, postoperatively.

Patients in this cohort must meet the following criteria:

- Patient operated on for brain metastasis as part of care, and diagnosed with lung cancer.

Intervention, the following volumes of blood will be drawn at each visit :

  • 2*8ml (EDTA tubes)
  • 1*8mL PBMC (only for patients receiving immunotherapy, collected before the 1st course of treatment, before the 2nd course of treatment, and at relapse)
  • 1*6mL Paxgene (only for patients with lung cancer of non-epidermoid histology, collected at 1st treatment, 2nd treatment and relapse)

Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

Patients will be sampled from 1 x 8 mL PBMC

Patients will be sampled from 1 x 8 mL of blood with Paxgene Tube

다른: Healthy Controls :

A population of healthy subjects will also be included. These healthy subjects will be either :

  • Companions of patients with lung cancer who have come to the oncology clinic for their loved ones.
  • Patients who have undergone atypical lung resection as part of their care for pneumothorax.

Intervention : Healthy subject will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

In addition to blood samples from healthy subjects, healthy tissue remnants from atypical lung resections performed as part of care for pneumothorax management will be used to analyze the study objectives.

A maximum of 30 healthy subjects are expected in this population.

Patients will be sampled from 2 x 8 mL blood tubes (EDTA tubes)

다른: Ancillary study

Patients included in the other arms of the cohort may also participate in the ancillary study if they meet the following conditions :

Being carriers of metastatic KRAS G12C mutated NSCLC with a treatment plan involving sotorasib, adagrasib, or another KRAS inhibitor, either alone or in combination with another treatment.

A target of 40 patients (among the 700 patients included in the cohort, excluding healthy subjects) is set for the ancillary study.

Regarding the ancillary study, as part of the care, patients are biopsied at diagnosis and during relapse(s). For metastatic patients with multiple sites, one site (the most accessible) is chosen and biopsied in interventional radiology or pulmonology.

The material used is: 17-18G biopsy needle / Sampling chamber volume of 0.01 cm³ to 0.02 cm³.

For a standard biopsy as part of the care, 3 samples are taken (total volume of 0.03 cm³ to 0.06 cm³). Inclusion in the ancillary study would add one sample using the same biopsy path, resulting in an additional volume of 0.01 cm³ to 0.02 cm³.

In the case of a complex biopsy, no additional sampling related to the research will be performed.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall survival
기간: up to 5 years

Overall survival will be defined as the time elapsed between the date of the initial diagnosis of lung cancer and the date of death, regardless of the cause. Patients still alive at the end of the follow-up period will complete their participation in the cohort.

up to 5 years

2차 결과 측정

결과 측정
측정값 설명
기간
Describe the care pathway for patients with lung cancer. Assess the time intervals between different steps in the initial management of lung cancer.
기간: up to 5 years

The care pathway will be described through the collection of dates (surgery, radiotherapy, presentation at multidisciplinary consultation meetings, etc.) and types of medical consultations.

up to 5 years
Evaluate the return to work for patients of working age who have been treated for lung cancer.
기간: up to 5 years

Proportion of patients who returned to work after treatment, measurement of the average time taken, and factors associated with the return to work.

up to 5 years
Identify specific biomarkers of lung cancer cells (primary tumors or metastatic tissues) in comparison to healthy lung tissues.
기간: up to 5 years

Quantitative comparison and characterization of biomarkers (extracellular vesicles and miRNA signatures) between tumor tissues and non-cancerous tissues.

up to 5 years
Evaluate the prognostic and predictive value of circulating biomarkers at diagnosis and during systemic treatments.
기간: up to 5 years

Association between levels of circulating biomarkers and overall survival as well as treatment response.

up to 5 years

기타 결과 측정

결과 측정
기간
종양 및 혈장 샘플의 종적 분석을 통한 KRAS G12C 억제제에 대한 내성 발생 메커니즘 예측.
기간: 최대 5년
최대 5년
종양 및 혈장 샘플의 종적 분석을 통해 KRAS G12C 억제제에 대한 내성 발달 메커니즘 규명
기간: 최대 5년
최대 5년
전사적 변화가 sotorasib 또는 adagrasib 하에서 전이성 KRAS G12C 돌연변이 비소세포폐암 환자의 무진행 생존율을 예측할 수 있는지 여부를 결정합니다.
기간: 최대 5년
최대 5년
치료 중 발생하는 특정 분자적 변화의 검출에 대한 예후적 가치 평가
기간: 최대 5년
최대 5년
진행 중인 환자의 종양 및 혈장 샘플에서 새로운 분자 변이를 검출할 수 있는지 확인.
기간: 최대 5년
최대 5년

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 12월 10일

기본 완료 (추정된)

2029년 12월 1일

연구 완료 (추정된)

2034년 12월 1일

연구 등록 날짜

최초 제출

2024년 5월 23일

QC 기준을 충족하는 최초 제출

2024년 6월 28일

처음 게시됨 (실제)

2024년 7월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다